Efficacy

Xpovio (Selinexor) Efficacy in Treating Lymphoma

Xpovio (selinexor) is a prescription medicine that has been approved by the Food and Drug Administration (FDA) for the treatment of certain types of lymphoma. Specifically, it is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. Selinexor functions as a selective inhibitor of nuclear export, which blocks the nuclear export protein XPO1. This action leads to the accumulation of tumor suppressor proteins in the cell nucleus, potentially restoring their ability to halt cancer growth.

The efficacy of Xpovio in treating lymphoma was demonstrated in a multicenter, single-arm, open-label clinical trial known as the SADAL study. This study evaluated the response rate in patients with relapsed or refractory DLBCL who had received two to five prior lines of therapy. The results showed an overall response rate (ORR) of 28%, with 13% of patients achieving a complete response (CR) and 15% achieving a partial response (PR). The median duration of response (DOR) for those achieving a response was 23.0 months, indicating a significant duration of efficacy for those who respond to the treatment.

Columvi (Glofitamab-gxbm) Efficacy in Treating Lymphoma

Columvi (glofitamab-gxbm) is currently being investigated as a treatment for various types of B-cell lymphomas. Glofitamab is a bispecific monoclonal antibody designed to bind to both CD20 on B-cells and CD3 on T-cells, thereby engaging and activating T-cells to exert cytotoxic effects on the B-cell lymphoma cells. While not yet approved by regulatory agencies, clinical trials are ongoing to evaluate its efficacy and safety in patients with lymphoma.

In the clinical trials conducted so far, glofitamab has shown promise in the treatment of relapsed or refractory non-Hodgkin's lymphoma, including DLBCL. Preliminary data from these trials suggest that glofitamab can induce high response rates, even in patients who have failed multiple prior lines of therapy. The response rates and durability of response are being closely monitored to better understand the potential role of glofitamab in the treatment landscape of lymphoma. As the clinical trial data matures, more information will be available to assess the full efficacy profile of Columvi in treating lymphoma.